Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
54.08
-1.28 (-2.31%)
At close: Jan 31, 2025, 4:00 PM
54.04
-0.04 (-0.07%)
After-hours: Jan 31, 2025, 5:12 PM EST
Akero Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
56
Market Cap
3.77B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
AKRO News
- 1 day ago - Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 1 day ago - Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation - Accesswire
- 3 days ago - Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 days ago - Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients - Seeking Alpha
- 4 days ago - Akero Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 5 days ago - Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results - Investopedia
- 5 days ago - Why did Akero (AKRO) stock soar 110% on Monday? - Invezz